Zacks Investment Research upgraded shares of argenx (NASDAQ:ARGX) from a hold rating to a buy rating in a research note published on Monday morning. The brokerage currently has $104.00 price objective on the stock.

According to Zacks, “argenx SE is a biopharmaceutical company. It focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company’s product pipeline consists of ARGX-113, ARGX-110 and ARGX-111 which are in clinical trials. argenx SE is based in Breda, the Netherlands. “

ARGX has been the subject of several other reports. Stifel Nicolaus reaffirmed a buy rating on shares of argenx in a research report on Thursday, November 1st. JMP Securities upped their price objective on argenx to $150.00 and gave the stock an outperform rating in a research report on Monday, September 17th. SunTrust Banks upped their price objective on argenx to $132.00 and gave the stock an in-line rating in a research report on Tuesday, September 18th. Wedbush reaffirmed an outperform rating and set a $125.00 price objective (down from $130.00) on shares of argenx in a research report on Monday, November 5th. Finally, Piper Jaffray Companies reaffirmed an overweight rating and set a $154.00 price objective on shares of argenx in a research report on Monday, September 17th. One equities research analyst has rated the stock with a hold rating and nine have given a buy rating to the company. argenx has an average rating of Buy and a consensus price target of $134.38.

NASDAQ:ARGX opened at $84.72 on Monday. The stock has a market cap of $3.00 billion, a PE ratio of -60.51 and a beta of 1.60. argenx has a 1 year low of $24.14 and a 1 year high of $103.02.

Institutional investors have recently bought and sold shares of the company. Atria Investments LLC purchased a new stake in shares of argenx in the 2nd quarter valued at about $213,000. Capital Fund Management S.A. purchased a new stake in shares of argenx in the 3rd quarter valued at about $212,000. Stevens Capital Management LP purchased a new stake in shares of argenx in the 3rd quarter valued at about $214,000. Fred Alger Management Inc. lifted its holdings in shares of argenx by 50.0% in the 2nd quarter. Fred Alger Management Inc. now owns 3,000 shares of the company’s stock valued at $249,000 after purchasing an additional 1,000 shares during the last quarter. Finally, Wedbush Securities Inc. purchased a new stake in shares of argenx in the 3rd quarter valued at about $258,000. 59.52% of the stock is owned by institutional investors and hedge funds.

About argenx

argenx SE, a clinical-stage biopharmaceutical company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases and cancer. The company's lead product candidates include ARGX-113 that completed Phase 2 clinical trials for the treatment of autoimmune diseases, including myasthenia gravis, immune thrombocytopenia, and pemphigus vulgaris; and ARGX-110, which is in Phase 1/2 clinical trials for the treatment of T-cell lymphoma, acute myeloid leukemia, and myelodysplastic syndrome.

Featured Story: How to calculate the annual rate of depreciation

Get a free copy of the Zacks research report on argenx (ARGX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for argenx (NASDAQ:ARGX)

Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.